Impact of FDG-PET/CT in the management of lymphoma

[1]  B. Coiffier,et al.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.

[2]  Sang-We Kim,et al.  Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP , 2011, Annals of Hematology.

[3]  Andrew Homb,et al.  18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.

[4]  Ora Israel,et al.  18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients , 2010, Journal of Nuclear Medicine.

[5]  R. Matthews,et al.  Radiologic Clinics of North America: Imaging of Lymphoma , 2009, Journal of Nuclear Medicine.

[6]  M. Dietlein,et al.  FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  B. Cheson.  The case against heavy PETing. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Rahmouni,et al.  Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy , 2009, Journal of Nuclear Medicine.

[9]  Michel Meignan,et al.  Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.

[10]  H. Amthauer,et al.  Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. , 2008, Blood.

[11]  J. Leonard,et al.  Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  M. Mancini,et al.  Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma , 2008, La radiologia medica.

[13]  J. Rademaker.  Radiologic clinics of North America. Imaging of Lymphoma. Preface. , 2008, Radiologic clinics of North America.

[14]  M. Juweid.  18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence? , 2007, Journal of Nuclear Medicine.

[15]  A. Nagler,et al.  Combined escBEACOPP-ABVD Therapy for Advanced Hodgkin’s Lymphoma Patients with High IPS Score: An Effective Regimen and Low Positive Predictive Value of Early FDG-PET/CT Scan. , 2007 .

[16]  B. Cheson,et al.  The role of FDG-PET scans in patients with lymphoma. , 2007, Blood.

[17]  Emmanuel Itti,et al.  Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.

[18]  K. Ohtomo,et al.  FDG-PET in T-cell and NK-cell neoplasms. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Wolfgang A Weber,et al.  18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative? , 2007, Journal of Nuclear Medicine.

[20]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Levis,et al.  Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi , 2007, Annals of Hematology.

[22]  M. Senda,et al.  Diagnostic performance of CT, PET, side-by-side, and fused image interpretations for restaging of non-Hodgkin lymphoma , 2007, Annals of nuclear medicine.

[23]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Brepoels,et al.  PET and PET/CT for response evaluation in lymphoma: Current practice and developments , 2007, Leukemia & lymphoma.

[26]  L. Mortelmans,et al.  Hodgkin lymphoma: Response assessment by Revised International Workshop Criteria , 2007, Leukemia & lymphoma.

[27]  J. Yahalom.  Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat , 2007, Leukemia & lymphoma.

[28]  J. Armitage,et al.  F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas , 2007, Leukemia & lymphoma.

[29]  M. Salvatore,et al.  Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans , 2007, Leukemia & lymphoma.

[30]  J. Leonard,et al.  FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease , 2006, Cancer.

[31]  J. Coya,et al.  PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  S. Pileri,et al.  Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  P. Solal-Céligny.  Follicular lymphoma international prognostic index , 2006, Current treatment options in oncology.

[34]  B. Cheson,et al.  Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.

[35]  M. Blaufox,et al.  A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphoma , 2005, Cancer.

[36]  M. O'Doherty,et al.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Emmanuel Itti,et al.  [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.

[38]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Vose,et al.  Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  B. Cheson,et al.  Role of positron emission tomography in lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  N. Mikhaeel,et al.  Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  J. Ioannidis,et al.  18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[43]  M. Heldmann,et al.  Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's disease. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Osman Ratib,et al.  Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[45]  N. Tamaki,et al.  18p-FDG PET is superior to67Ga SPECT in the staging of non-Hodgkin’s lymphoma , 2004 .

[46]  Thomas F Hany,et al.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? , 2004, Radiology.

[47]  Thomas Beyer,et al.  FDG-PET/CT in re-staging of patients with lymphoma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[48]  B. Beuthien-Baumann,et al.  Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma , 2004, British Journal of Cancer.

[49]  H. Bartelink,et al.  Long-term cause-specific mortality of patients treated for Hodgkin's disease. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  V. Diehl,et al.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. , 2003, The New England journal of medicine.

[51]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[52]  S. Rankin.  Assessment of response to therapy using conventional imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[53]  P. Dupont,et al.  Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  J. Leonard,et al.  PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  Kazutaka Hayashi,et al.  Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma , 2002, Annals of nuclear medicine.

[56]  R. Fisher,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. , 2002, The American journal of medicine.

[57]  Frank Grünwald,et al.  Positron Emission Tomography for the Staging of Hodgkin's Lymphoma - Increasing the Body of Evidence in Favor of the Method , 2002, Acta oncologica.

[58]  B Beuthien-Baumann,et al.  Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma , 2001, British journal of haematology.

[59]  V. Diehl,et al.  Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.

[60]  C D Claussen,et al.  Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. , 2001, Oncology reports.

[61]  P. Dupont,et al.  Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.

[62]  R. Hustinx,et al.  Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  H. Schirrmeister,et al.  2‐(fluorine‐18)fluoro‐2‐deoxy‐D‐glucose positron emission tomography in the detection and staging of malignant lymphoma , 2001, Cancer.

[64]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  F. Maul,et al.  Whole body positron emission tomography in the treatment of Hodgkin disease , 2001, Cancer.

[66]  S. Hain,et al.  2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[67]  S. Hain,et al.  18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT , 2000, Leukemia & lymphoma.

[68]  F. Gherlinzoni,et al.  The role of positron emission tomography (PET) in the management of lymphoma patients. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[70]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[72]  J Kotzerke,et al.  Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  M Schwaiger,et al.  Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.

[74]  E. Merkle,et al.  Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.

[75]  J Kotzerke,et al.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. , 1997, Radiology.

[76]  D. Neuberg,et al.  Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  J. Armitage,et al.  Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  H. Minn,et al.  Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. , 1995, Blood.

[79]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[80]  A G Stansfeld,et al.  Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[81]  P. Stomper,et al.  Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  E. Jaffe,et al.  Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  G. Canellos,et al.  Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  D. Weisenburger,et al.  Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  A. Serafini,et al.  FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. , 2010, Radiographics : a review publication of the Radiological Society of North America, Inc.

[87]  C. Copie-Bergman,et al.  Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  S. Pileri,et al.  Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma , 2009 .

[89]  W. Sperr,et al.  Rituximab for the treatment of acquired antibodies to factor VIII. , 2007, Haematologica.

[90]  Lotty Hooft,et al.  18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. , 2006, Haematologica.

[91]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[92]  F. d'Amore,et al.  Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. , 2006, Haematologica.

[93]  M. Juweid.  Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. , 2006, Hematology. American Society of Hematology. Education Program.

[94]  A. Levis,et al.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. , 2006, Haematologica.

[95]  R. Hustinx,et al.  Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  B. Krug,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease , 2001, Annals of Hematology.

[97]  R. Buchert,et al.  18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[98]  S. Hain,et al.  18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[99]  G. Jerusalem,et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.

[100]  O. Israel,et al.  Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. , 2000, Radiology.

[101]  J Kotzerke,et al.  Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. , 1999, Acta oncologica.

[102]  S. Ascani,et al.  Erythrophagocytosis by neoplastic cells in a patient with myelodysplastic syndrome. , 1998 .

[103]  D. Bumann,et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.